scholarly journals The Spleen as an Optimal Site for Islet Transplantation and a Source of Mesenchymal Stem Cells

2018 ◽  
Vol 19 (5) ◽  
pp. 1391 ◽  
Author(s):  
Naoaki Sakata ◽  
Gumpei Yoshimatsu ◽  
Shohta Kodama
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Islet Transplantation ◽  
Optimal Site

scholarly journals Spleen, as an Optimal Site for Islet Transplantation and a Source of Mesenchymal Stem Cells

2018 ◽  
Author(s):  
Naoaki Sakata ◽  
Gumpei Yoshimatsu ◽  
Shohta Kodama
Keyword(s):  
Diabetes Mellitus ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Islet Transplantation ◽  
Clinical Success ◽  
Severe Diabetes ◽  
Clinical Islet Transplantation ◽  
Long Time ◽  
Optimal Site

In this review, we show the unique potential of spleen as an optimal site for islet transplantation and a source of mesenchymal stem cells. Islet transplantation is a cellular replacement therapy to treat severe diabetes mellitus, but its clinical outcome is unsatisfactory at present. One factor in clinical success of this therapy is selection of the most appropriate transplantation site. The spleen has been studied for a long time as a candidate site for islet transplantation. Its advantages include physiological insulin drainage and regulation of immunity. Recently it has also been shown that the spleen contributes to the regeneration of transplanted islets. The efficacy of transplantation is not as high as that obtained with intraportal transplantation, which is the current representative method of clinical islet transplantation. Safer and more effective methods of islet transplantation need to be established before the spleen can be effectively used in the clinic. Spleen also has an interesting aspect as a mesenchymal stem cell reservoir. The splenic mesenchymal stem cells contribute to tissue repair in damaged tissue, and thus, the infusion can be a promising therapy for autoimmune diseases, including type 1 diabetes mellitus and Sjogren’s syndrome.

The Effect and Mechanism of Bone Marrow-Derived Mesenchymal Stem Cells On Intramuscular Islet Transplantation.

2014 ◽  
Vol 98 ◽  
pp. 332
Author(s):  
G. Yoshimatsu ◽  
N. Sakata ◽  
H. Tsuchiya ◽  
T. Minowa ◽  
T. Takemura ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Islet Transplantation

A novel method for performing islet transplantation using tissue engineered sheets composed of islets and mesenchymal stem cells

2014 ◽  
Vol 219 (4) ◽  
pp. e49-e50
Author(s):  
Masataka Hirabaru ◽  
Tamotsu Kuroki ◽  
Amane Kitasato ◽  
Tomohiko Adachi ◽  
Hajime Matsushima ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Islet Transplantation ◽  
Novel Method

scholarly journals Regenerative Therapy of Type 1 Diabetes Mellitus: From Pancreatic Islet Transplantation to Mesenchymal Stem Cells

2016 ◽  
Vol 2016 ◽  
pp. 1-22 ◽  
Author(s):  
Nadine E. Rekittke ◽  
Meidjie Ang ◽  
Divya Rawat ◽  
Rahul Khatri ◽  
Thomas Linn
Keyword(s):  
Stem Cells ◽  
Type 1 Diabetes ◽  
Mesenchymal Stem Cells ◽  
Islet Transplantation ◽  
Pancreatic Islet ◽  
Graft Function ◽  
Individual Therapy ◽  
Regenerative Therapy ◽  
Pancreatic Islet Transplantation

Type 1 diabetes is an autoimmune disease resulting in the permanent destruction of pancreatic islets. Islet transplantation to portal vein provides an approach to compensate for loss of insulin producing cells. Clinical trials demonstrated that even partial islet graft function reduces severe hypoglycemic events in patients. However, therapeutic impact is restrained due to shortage of pancreas organ donors and instant inflammation occurring in the hepatic environment of the graft. We summarize on what is known about regenerative therapy in type 1 diabetes focusing on pancreatic islet transplantation and new avenues of cell substitution. Metabolic pathways and energy production of transplanted cells are required to be balanced and protection from inflammation in their intravascular bed is desired. Mesenchymal stem cells (MSCs) have anti-inflammatory features, and so they are interesting as a therapy for type 1 diabetes. Recently, they were reported to reduce hyperglycemia in diabetic rodents, and they were even discussed as being turned into endodermal or pancreatic progenitor cells. MSCs are recognized to meet the demand of an individual therapy not raising the concerns of embryonic or induced pluripotent stem cells for therapy.

Sign in / Sign up

Export Citation Format

Share Document